DUAL ELIGIBLES: Health Plans, CMS Agree To Reimburse States; Stopgap Drug Coverage for Dual Eligibles

Why This Topic Matters

It helps readers understand a temporary federal response to drug coverage disruptions affecting dual eligibles, along with the policy and reimbursement implications for states, plans, pharmacies, and Congress.

Article Sections

1. Stopgap coverage and reimbursement response

   The article describes the early Part D transition issues, the temporary state coverage response, and the initial federal and health plan positions on reimbursement.

2. Misinformation ignites reaction from health plans, Senate groups

   This section summarizes stakeholder reactions, including Senate legislative proposals and broader concerns about coverage disruptions and reimbursement responsibility.

3. CMS, HHS see states as 'payers of last resort'

   The final section covers a closed-door federal and Senate meeting, the temporary reimbursement framework, and the ongoing possibility of legislative action.